SARS-CoV-2 vaccination, Parkinson's disease, and other movement disorders: case series and short literature review.
COVID-19
/ prevention & control
COVID-19 Vaccines
/ adverse effects
Carbidopa
/ therapeutic use
Deep Brain Stimulation
Drug Combinations
Humans
Immunization, Secondary
/ adverse effects
Levodopa
/ therapeutic use
Male
Middle Aged
Movement Disorders
/ etiology
Parkinson Disease
/ etiology
Treatment Outcome
Vaccination
/ adverse effects
Booster vaccination
COVID-19 vaccine
Movement disorders
Parkinson’s disease
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
01
05
2022
accepted:
25
05
2022
pubmed:
7
6
2022
medline:
20
8
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Several neurological complications have been reported following SARS-Cov-2 vaccination, without a clear causal relationship ever being verified, including some cases of worsening of Parkinson's disease (PD) symptoms and new onset of movement disorders in non-parkinsonian patients. We describe two new cases of PD patients treated with device-aided therapy who developed worsening of parkinsonian symptoms after receiving the third vaccine dose (booster). We also conducted a short review of the cases reported in literature of PD symptoms worsening and new onset of movement disorders in non-parkinsonian patients after SARS-Cov-2 vaccination. The first patient, a 46-year-old man implanted with bilateral Subthalamic Deep Brain Stimulation, experienced temporary motor and non-motor symptoms worsening after mRNA-1273 booster, improved after stimulation settings modification. The second patient, a 55-year-old man implanted with percutaneous endoscopic transgastric jejunostomy (PEG-J) for levodopa-carbidopa intestinal gel (LCIG) infusion experienced severe temporary worsening of dyskinesia and managed through temporary LCIG dose reduction. Other seven cases of vaccine-related movement disorder are currently reported in literature, four describing PD symptoms worsening and three the onset of new movement disorders in otherwise healthy people. Both our patients and the cases described so far completely recovered after few days with parkinsonian therapy modification, symptomatic treatment, or even spontaneously, underlining the transient and benign nature of side effects from vaccine. Patients should be reassured about these complications, manageable through a prompt evaluation by the reference neurologist.
Sections du résumé
BACKGROUND
BACKGROUND
Several neurological complications have been reported following SARS-Cov-2 vaccination, without a clear causal relationship ever being verified, including some cases of worsening of Parkinson's disease (PD) symptoms and new onset of movement disorders in non-parkinsonian patients.
METHODS
METHODS
We describe two new cases of PD patients treated with device-aided therapy who developed worsening of parkinsonian symptoms after receiving the third vaccine dose (booster). We also conducted a short review of the cases reported in literature of PD symptoms worsening and new onset of movement disorders in non-parkinsonian patients after SARS-Cov-2 vaccination.
RESULTS
RESULTS
The first patient, a 46-year-old man implanted with bilateral Subthalamic Deep Brain Stimulation, experienced temporary motor and non-motor symptoms worsening after mRNA-1273 booster, improved after stimulation settings modification. The second patient, a 55-year-old man implanted with percutaneous endoscopic transgastric jejunostomy (PEG-J) for levodopa-carbidopa intestinal gel (LCIG) infusion experienced severe temporary worsening of dyskinesia and managed through temporary LCIG dose reduction. Other seven cases of vaccine-related movement disorder are currently reported in literature, four describing PD symptoms worsening and three the onset of new movement disorders in otherwise healthy people.
CONCLUSION
CONCLUSIONS
Both our patients and the cases described so far completely recovered after few days with parkinsonian therapy modification, symptomatic treatment, or even spontaneously, underlining the transient and benign nature of side effects from vaccine. Patients should be reassured about these complications, manageable through a prompt evaluation by the reference neurologist.
Identifiants
pubmed: 35666352
doi: 10.1007/s10072-022-06182-w
pii: 10.1007/s10072-022-06182-w
pmc: PMC9167915
doi:
Substances chimiques
COVID-19 Vaccines
0
Drug Combinations
0
Levodopa
46627O600J
Carbidopa
MNX7R8C5VO
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
5165-5168Informations de copyright
© 2022. Fondazione Società Italiana di Neurologia.
Références
Garg RK, Paliwal VK (2022) Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci 43:3–40. https://doi.org/10.1007/s10072-021-05662-9
doi: 10.1007/s10072-021-05662-9
pubmed: 34719776
Bloem BR, Trenkwalder C, Sanchez-Ferro A, Kalia LV, Alcalay R, Chiang HL, Kang UJ, Goetz C, Brundin P, Papa SM (2021) COVID-19 vaccination for persons with Parkinson’s disease: light at the end of the tunnel? J Parkinsons Dis 11:3–8. https://doi.org/10.3233/JPD-212573
doi: 10.3233/JPD-212573
pubmed: 33523021
pmcid: 7990445
Antonini A, Leta V, Teo J, Chaudhuri KR (2020) Outcome of Parkinson’s disease patients affected by COVID-19. Mov Disord 35:905–908. https://doi.org/10.1002/mds.28104
doi: 10.1002/mds.28104
pubmed: 32347572
pmcid: 7267273
Schneider SA, Hennig A, Martino D (2021) Relationship between COVID-19 and movement disorders: a narrative review. Eur J Neurol 29:1243–1253. https://doi.org/10.1111/ene.15217
doi: 10.1111/ene.15217
pubmed: 34918437
Erro R, Buonomo AR, Barone P, Pellecchia MT (2021) Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson’s disease. Mov Disord 36:2219. https://doi.org/10.1002/mds.28772
doi: 10.1002/mds.28772
pubmed: 34368991
pmcid: 8441657
Cosentino C, Torres L, Vélez M, Nuñez Y, Sánchez D, Armas C, Alvarado M (2022) SARS-CoV-2 vaccines and motor symptoms in Parkinson’s disease. Mov Disord 37:233. https://doi.org/10.1002/mds.28851
doi: 10.1002/mds.28851
pubmed: 34775612
Matar E, Manser D, Spies JM, Worthington JM, Parratt KL (2021) Acute hemichorea-hemiballismus following COVID-19 (AZD1222) vaccination. Mov Disord 36:2714–2715. https://doi.org/10.1002/mds.28796
doi: 10.1002/mds.28796
pubmed: 34581453
pmcid: 8661968
Ryu DW, Lim EY, Cho AH (2022) A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine. Neurol Sci 43:771–773. https://doi.org/10.1007/s10072-021-05763-5
doi: 10.1007/s10072-021-05763-5
pubmed: 34811599
Shi Y, Guo M, Yang W, Liu S, Zhu B, Yang L, Yang C, Liu C (2021) Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases? Expert Rev Vaccines 20:375–383. https://doi.org/10.1080/14760584.2021.1911653
doi: 10.1080/14760584.2021.1911653
pubmed: 33787439
Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener 4:19. https://doi.org/10.1186/s40035-015-0042-0
doi: 10.1186/s40035-015-0042-0
pubmed: 26464797
pmcid: 4603346
Brugger F, Erro R, Balint B et al (2015) Why is there motor deterioration in Parkinson’s disease during systemic infections-a hypothetical view. NPJ Parkinsons Dis 1:15014. https://doi.org/10.1038/npjparkd.2015.14
doi: 10.1038/npjparkd.2015.14
pubmed: 28725683
pmcid: 5516617
Munro APS, Janani L, Cornelius V,: COV-BOOST study group, et al (2021) Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398:2258–2276. https://doi.org/10.1016/S0140-6736(21)02717-3
doi: 10.1016/S0140-6736(21)02717-3
pubmed: 34863358
pmcid: 8639161